Aug 21- Eli Lilly and Co said its experimental psoriasis drug was found to be more effective in clearing skin than a generic treatment and a placebo in late-stage studies. The most common inflammatory disease in the United States- it can occur on any part of the body- it is associated with diabetes and heart disease.» Read More
British health authorities today announced that starting next fall, all 12- and 13-year-old girls will have to get the controversial shots to prevent the sexually transmitted virus that can lead to cervical cancer. Merck and Sanofi-Aventis are partners on the vaccine Gardasil and the UK-based GlaxoSmithKline makes a similar one Cervarix.
If the stock closes down at least 4.46% today (as I write this it is off nearly 7%) Eli Lilly will suffer its worst one-day loss in more than four years, according to our resident statistical expert Robert Hum. If it were to close off more than 7.79%, Hum says it would be the stock's biggest one-day fall since Oct. 23, 2002--almost five years to the day.
Even as much of the economy contracts, health care continues to grow, and investment opportunities continue to grow with it. What to choose among those investment opportunities? Analyst Michael Magiera of Manning & Napier looks past some of the more volatile pharmaceutical stocks.
Bristol-Myers Squibb Thursday said third-quarter earnings more than doubled on higher drug revenue, including a strong rebound for its Plavix blood-clot preventer, and raised its 2007 profit forecast.
Eli Lilly said it stopped giving its experimental blood-clot preventer prasugrel to heart patients in two small trials, noting that the dosage of the drug may have to be adjusted for certain types of patients.
On a day when the markets are selling off, shares of the world's biggest biotech company--by sales--are holding their own. There are a few things that could be buoying Amgen's stock. The company won a huge patent battle yesterday, it reports earnings after the closing bell today and an analyst has upgraded the stock to "Outperform".
Major European indexes closed lower after U.S. existing-homes sales fell 8% in September to a record low 5.04 million unit because of troubles in the subprime mortgages and credit markets.
Shares in the world's second biggest drug company, GlaxoSmithKline, are giving back all of yesterday's gains in early trading this morning. That's because sales of its embattled diabetes drug, Avandia and other Avandia-related products took a huge dive in the third quarter. Down 48% in the U.S. from the same time last year.
GlaxoSmithKline posted a lower profit on Wednesday due to tumbling sales of its Avandia diabetes drug, generic competition and pressure on top-selling asthma treatment Advair, and said it would cut jobs to save costs.
German pharmaceutical and chemical company Merck KGaA said Wednesday that its third-quarter profit fell 75 percent because of costs related to its purchase of Swiss biotech firm Serono.
Does Big Pharma need a modern day match-maker? With so many weak pipelines, the Fast Money traders think some could use a mate!
It isn't moving the stock, but Dendreon this morning announced that it has signed up all of the patients for the big clinical trial that could lead to its prostate cancer drug, Provenge, winning Food and Drug Administration approval. The completion of enrollment was not unexpected, so that's why people aren't trading on the news.
A Boston jury Tuesday found that the patents on Amgen's top-selling anemia drugs are valid, blocking Roche from launching a rival medicine in the United States and sending Amgen shares up more than 2 percent.
Biotech giant Biogen Idec posted some disappointing third-quarter results, falling short of Wall Street expectations across the board. Does it matter, since the company has announced it's up for sale? Biotech analyst Christopher Raymond of Robert W. Baird thinks it does.
SGP took a beating after it missed its earnings, but investors shouldn't lose hope. Cramer talks to CEO Fred Hassan to find out what's on the horizon.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Biotechnology company Biogen Idec, which put itself up for sale earlier this month, reported third-quarter earnings and revenue Tuesday that fell short of analysts' expectations.
What can I say? I love alliteration. But investors in the drugmaker are probably in no mood for a cute, clever turn of phrase. SGP is absolutely getting hammered this morning after coming in with third quarter earnings below expectations.
To a five-star fund manager, it's not how big the stars are, but how brightly they're shining. In the pharmaceutical field, Kris Jenner of T. Rowe Price finds brightness at both ends of the size spectrum.
Will Friday’s sell-off have a dramtaic impact on Monday's trading and the earnings flood that lies ahead?
Schering-Plough on Monday reported third-quarter profit and sales that fell short of Wall Street's target, sending shares down more than 10 percent amid concerns about its flagship cholesterol drugs